278 related articles for article (PubMed ID: 28594553)
1. Development of Protein Degradation Inducers of Androgen Receptor by Conjugation of Androgen Receptor Ligands and Inhibitor of Apoptosis Protein Ligands.
Shibata N; Nagai K; Morita Y; Ujikawa O; Ohoka N; Hattori T; Koyama R; Sano O; Imaeda Y; Nara H; Cho N; Naito M
J Med Chem; 2018 Jan; 61(2):543-575. PubMed ID: 28594553
[TBL] [Abstract][Full Text] [Related]
2.
Ohoka N; Okuhira K; Ito M; Nagai K; Shibata N; Hattori T; Ujikawa O; Shimokawa K; Sano O; Koyama R; Fujita H; Teratani M; Matsumoto H; Imaeda Y; Nara H; Cho N; Naito M
J Biol Chem; 2017 Mar; 292(11):4556-4570. PubMed ID: 28154167
[TBL] [Abstract][Full Text] [Related]
3. Derivatization of inhibitor of apoptosis protein (IAP) ligands yields improved inducers of estrogen receptor α degradation.
Ohoka N; Morita Y; Nagai K; Shimokawa K; Ujikawa O; Fujimori I; Ito M; Hayase Y; Okuhira K; Shibata N; Hattori T; Sameshima T; Sano O; Koyama R; Imaeda Y; Nara H; Cho N; Naito M
J Biol Chem; 2018 May; 293(18):6776-6790. PubMed ID: 29545311
[TBL] [Abstract][Full Text] [Related]
4. Different Degradation Mechanisms of Inhibitor of Apoptosis Proteins (IAPs) by the Specific and Nongenetic IAP-Dependent Protein Eraser (SNIPER).
Ohoka N; Ujikawa O; Shimokawa K; Sameshima T; Shibata N; Hattori T; Nara H; Cho N; Naito M
Chem Pharm Bull (Tokyo); 2019 Mar; 67(3):203-209. PubMed ID: 30369550
[TBL] [Abstract][Full Text] [Related]
5. Identification of novel androgen receptor degrading agents to treat advanced prostate cancer.
Wu H; Ren J; Zhao L; Li Z; Ye W; Yang Y; Wang J; Bian J
Eur J Med Chem; 2021 May; 217():113376. PubMed ID: 33756125
[TBL] [Abstract][Full Text] [Related]
6. Specific non-genetic IAP-based protein erasers (SNIPERs) as a potential therapeutic strategy.
Ma Z; Ji Y; Yu Y; Liang D
Eur J Med Chem; 2021 Apr; 216():113247. PubMed ID: 33652355
[TBL] [Abstract][Full Text] [Related]
7. Small-Molecule-Mediated Degradation of the Androgen Receptor through Hydrophobic Tagging.
Gustafson JL; Neklesa TK; Cox CS; Roth AG; Buckley DL; Tae HS; Sundberg TB; Stagg DB; Hines J; McDonnell DP; Norris JD; Crews CM
Angew Chem Int Ed Engl; 2015 Aug; 54(33):9659-62. PubMed ID: 26083457
[TBL] [Abstract][Full Text] [Related]
8. Structure-activity relationship of novel (benzoylaminophenoxy)phenol derivatives as anti-prostate cancer agents.
Kazui Y; Fujii S; Yamada A; Ishigami-Yuasa M; Kagechika H; Tanatani A
Bioorg Med Chem; 2018 Oct; 26(18):5118-5127. PubMed ID: 30228001
[TBL] [Abstract][Full Text] [Related]
9. Carnosic acid promotes degradation of the androgen receptor and is regulated by the unfolded protein response pathway in vitro and in vivo.
Petiwala SM; Li G; Bosland MC; Lantvit DD; Petukhov PA; Johnson JJ
Carcinogenesis; 2016 Aug; 37(8):827-838. PubMed ID: 27267997
[TBL] [Abstract][Full Text] [Related]
10. Multivalent peptidomimetic conjugates: a versatile platform for modulating androgen receptor activity.
Levine PM; Imberg K; Garabedian MJ; Kirshenbaum K
J Am Chem Soc; 2012 Apr; 134(16):6912-5. PubMed ID: 22509763
[TBL] [Abstract][Full Text] [Related]
11. The andean anticancer herbal product BIRM causes destabilization of androgen receptor and induces caspase-8 mediated-apoptosis in prostate cancer.
Shamaladevi N; Araki S; Lyn DA; Ayyathurai R; Gao J; Lokeshwar VB; Navarrete H; Lokeshwar BL
Oncotarget; 2016 Dec; 7(51):84201-84213. PubMed ID: 27705939
[TBL] [Abstract][Full Text] [Related]
12. Targeted protein degradation and drug discovery.
Naito M
J Biochem; 2022 Jul; 172(2):61-69. PubMed ID: 35468190
[TBL] [Abstract][Full Text] [Related]
13. Theranostic Pt(IV) Conjugate with Target Selectivity for Androgen Receptor.
Qin X; Fang L; Zhao J; Gou S
Inorg Chem; 2018 May; 57(9):5019-5029. PubMed ID: 29667815
[TBL] [Abstract][Full Text] [Related]
14. Iminoenamine based novel androgen receptor antagonist exhibited anti-prostate cancer activity in androgen independent prostate cancer cells through inhibition of AKT pathway.
Divakar S; Saravanan K; Karthikeyan P; Elancheran R; Kabilan S; Balasubramanian KK; Devi R; Kotoky J; Ramanathan M
Chem Biol Interact; 2017 Sep; 275():22-34. PubMed ID: 28757136
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological evaluation of nuclear receptor-degradation inducers.
Itoh Y; Kitaguchi R; Ishikawa M; Naito M; Hashimoto Y
Bioorg Med Chem; 2011 Nov; 19(22):6768-78. PubMed ID: 22014751
[TBL] [Abstract][Full Text] [Related]
16. Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands.
Han X; Zhao L; Xiang W; Qin C; Miao B; Xu T; Wang M; Yang CY; Chinnaswamy K; Stuckey J; Wang S
J Med Chem; 2019 Dec; 62(24):11218-11231. PubMed ID: 31804827
[TBL] [Abstract][Full Text] [Related]
17. Second-generation testosterone-platinum(II) hybrids for site-specific treatment of androgen receptor positive prostate cancer: Design, synthesis and antiproliferative activity.
Ouellette V; Côté MF; Gaudreault RC; Tajmir-Riahi HA; Bérubé G
Eur J Med Chem; 2019 Oct; 179():660-666. PubMed ID: 31279298
[TBL] [Abstract][Full Text] [Related]
18. Designed, synthesized and biological evaluation of proteolysis targeting chimeras (PROTACs) as AR degraders for prostate cancer treatment.
Liang JJ; Xie H; Yang RH; Wang N; Zheng ZJ; Zhou C; Wang YL; Wang ZJ; Liu HM; Shan LH; Ke Y
Bioorg Med Chem; 2021 Sep; 45():116331. PubMed ID: 34364224
[TBL] [Abstract][Full Text] [Related]
19. Capillarisin blocks prostate-specific antigen expression on activation of androgen receptor in prostate carcinoma cells.
Tsui KH; Chang YL; Feng TH; Hou CP; Lin YH; Yang PS; Lee BW; Juang HH
Prostate; 2018 Mar; 78(4):242-249. PubMed ID: 29164633
[TBL] [Abstract][Full Text] [Related]
20. GCP-mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor-dependent and -independent mechanisms.
Tepper CG; Vinall RL; Wee CB; Xue L; Shi XB; Burich R; Mack PC; de Vere White RW
Prostate; 2007 Apr; 67(5):521-35. PubMed ID: 17252539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
